NEWS

News Articles

Help Wanted at Covid-19 Testing Labs

October 13, 2020

Coronavirus pandemic has heightened longstanding labor shortages in America’s clinical laboratories Brandy Gunsolus’s staff at the Augusta University Medical Center has expanded laboratory operations to meet the nonstop demand for coronavirus testing. Many of the 23 technologists involved with Covid-19 testing are working overtime, running patient samples and chasing down scarce supplies—all while trying to…

Read More

Takeda group begins manufacturing COVID-19 plasma treatment ahead of approval

October 12, 2020

The Takeda Pharmaceutical Co-led group that is developing a blood plasma treatment for COVID-19 has started manufacturing while the late-stage trial to determine whether it works is ongoing, Takeda 4502.T Chief Executive Christophe Weber said on Monday. The group, known as the CoVIg Plasma Alliance, enrolled its first patient in the Phase III trial on Friday after…

Read More

Takeda, Other Firms Test Covid-19 Convalescent-Plasma Treatment

October 8, 2020

NIH funds study of high antibody concentrations combined with the antiviral remdesivir The National Institute of Allergy and Infectious Diseases said a group of companies including Japanese drugmaker Takeda Pharmaceutical Co. TAK +0.11% began testing an experimental treatment for hospitalized Covid-19 patients that is derived from the convalescent plasma of people who have recovered from the new coronavirus. The NIAID, a…

Read More

Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease

October 8, 2020

Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M Investigational medicine ARO-AAT to be co-developed and co-commercialized in the United States by Takeda and Arrowhead…

Read More

First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine

October 8, 2020

Osaka, JAPAN and King of Prussia, Pa., USA • The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19• The CoVIg-19 Plasma Alliance urges anyone who has recovered from COVID-19 to consider…

Read More

Abbott Releases ID NOW COVID-19 Interim Clinical Study Results from 1,003 People to Provide the Facts on Clinical Performance and to Support Public Health

October 7, 2020

-Data show ID NOW performance of 95.0% sensitivity and 97.9% specificity within seven days of symptom onset– ID NOW is the most studied COVID-19 test available; interim post-authorization study evaluated 1,003 people– To date, Abbott has shipped more than 12 million ID NOW tests to all 50 states and provided more than 30 million rapid…

Read More